Tag Directory / HEALTHCARE     showing 241–260 of 290



AHA President Rick Pollack to retire by end of 2026 / Fierce

fiercehealthcare - Longtime American Hospital Association President Rick Pollack will retire by the end of 2026, the organization announced on Wednesday.

#healthcare #publichealth #governmentpolicy


Wednesday, December 10, 2025, 6:23 pm / permalink 16812 / 3 stories in 3 months


Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial / American Association for Cancer Research

Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Wednesday, December 10, 2025, 11:22 am / permalink 16789 / 15 stories in 3 months


ACA approval hits new high as subsidies set to expire: 7 things to know / Beckers

Alan Condon / beckershospitalreview - Approval of the ACA recently climbed to a new high of 57% — driven largely by a surge in support among independents — even as pandemic‑era enhanced subsidies are set to expire Dec. 31 unless Congress acts, according to a survey published Dec. 8 by the Wes…

#healthcare #drugpricing #publichealth #governmentpolicy


Monday, December 8, 2025, 12:22 pm / permalink 16702 / 21 stories in 3 months


A single shot of HPV vaccine may be enough to fight cervical cancer, study finds / ABC News

go - A new study suggests a single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer

#healthcare #publichealth #vaccinesafety


Monday, December 8, 2025, 12:21 am / permalink 16678 / 3 stories in 3 months


CVS Health agrees to pay $37.8M to settle fraud allegations over insulin pens / Fierce

fiercehealthcare - CVS Health agreed to pay $37.76 million to settle allegations that it dispensed too many insulin pens to patients and improperly billed federal healthcare programs for those prescriptions.

#healthcare #pharmaceuticals #drugpricing #publichealth #corporatetakeover


Monday, December 8, 2025, 12:21 am / permalink 16679 / 2 stories in 3 months


Will All Newborns Still Receive Hepatitis B Shots? A Committee’s Vote Will Tell. / NYT

Apoorva Mandavilli / nytimes - The federal vaccine panel appointed by Health Secretary Robert F. Kennedy Jr. is likely to decide on Thursday that the shots should be delayed for infants whose mothers test negative for the virus.

#healthcare #publichealth #governmentpolicy #cdc #vaccinesafety


Sunday, December 7, 2025, 10:22 am / permalink 16672 / 6 stories in 3 months


California Discourages Wild Mushroom Foraging After Fatal Outbreak / NYT

Hannah Ziegler / nytimes - Officials said one person was killed and 20 others were poisoned after eating death cap mushrooms, which look and taste like safe mushrooms but can cause liver failure.

#healthcare #publichealth #governmentpolicy


Saturday, December 6, 2025, 8:21 pm / permalink 16668 / 3 stories in 3 months


Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder / MedCity

Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, December 6, 2025, 10:21 am / permalink 16661 / 2 stories in 3 months


Rabi Hanna: Excited to Participate in ASH-a-palooza at ASH25 / OncoDaily

oncodaily - Rabi Hanna, Chairman at Department of Pediatric Hematology-Oncology and BMT at Cleveland Clinic, shared a post on X: “Excited to participate in ASH-a-palooza at ASH25 BLOOD BUDDIES. Designed for undergraduates, medical […]

#healthcare


ASH25 Conference Buzz


ASH25 Research Highlights


Other


Pharma Innovations at ASH25


All Other Stories


Saturday, December 6, 2025, 7:21 am / permalink 16654 / 27 stories in 3 months


ACIP drops universal hepatitis B birth dose recommendation / Endpoints

Max Bayer / endpoints - A panel of CDC vaccine advisors has stopped recommending that all children receive the hepatitis B vaccine at birth, overruling scientific consensus and public health officials who pleaded that there was no grounded rationale for ...

#healthcare #publichealth #governmentpolicy #cdc #vaccinesafety


Friday, December 5, 2025, 11:22 am / permalink 16612 / 14 stories in 3 months


A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes / Fierce

fiercehealthcare - Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from 12 former commissioners of the agency.

#healthcare #publichealth #governmentpolicy #biotech #drugdevelopment #fda #vaccinesafety


Thursday, December 4, 2025, 10:23 am / permalink 16565 / 10 stories in 3 months


UK and US agree zero-tariff deal on pharmaceuticals / ABC News

go - Officials say the U.K. has sealed a deal securing a 0% tariff rate for all U.K. medicines exported to the U.S. for at least 3 years, in return for the U.K. spending more on new medicines

#healthcare #pharmaceuticals #drugpricing #governmentpolicy


Monday, December 1, 2025, 1:23 pm / permalink 16444 / 6 stories in 3 months


FDA approves all ages gene therapy for spinal condition / Beckers

Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Monday, December 1, 2025, 4:21 am / permalink 16428 / 2 stories in 3 months


Novo submits high-dose Wegovy for FDA approval using voucher / Endpoints

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment #fda


Saturday, November 29, 2025, 5:21 pm / permalink 16400 / 2 stories in 3 months


CASSANDRA-PACT-21 Trial Update: Preoperative PAXG vs mFOLFIRINOX in Resectable and Borderline Resectable PDAC / OncoDaily

oncodaily - The landscape of early-stage pancreatic ductal adenocarcinoma (PDAC) continues to evolve as clinicians move from surgery-first strategies toward perioperative treatment. Neoadjuvant and perioperative approaches have shown growing promise, yet no […]

#healthcare #pharmaceuticals #publichealth #drugdevelopment


Saturday, November 29, 2025, 9:21 am / permalink 16387 / 5 stories in 3 months


Tracking with care: The ethics of using location tracking technology with people living with dementia / Medical Express

medicalxpress - Imagine you're 83 years old, living with dementia in a long-term care home. Lately, your caregivers keep asking you to wear a bracelet on your wrist 24/7. They say it's for your safety, so they can locate you quickly when needed.

#healthcare #publichealth


Saturday, November 29, 2025, 5:21 am / permalink 16384 / 2 stories in 3 months


Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment


Tuesday, November 25, 2025, 10:21 am / permalink 16294 / 5 stories in 3 months


FDA Approves Pembrolizumab + Enfortumab Vedotin-ejfv for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer / OncoDaily

oncodaily - What Does FDA Approval Mean? The U.S. Food and Drug Administration (FDA) evaluates new cancer therapies to determine whether they are safe and effective for clinical use. Approval is based […]

#healthcare #pharmaceuticals #publichealth #drugdevelopment #fda


Monday, November 24, 2025, 10:23 am / permalink 16257 / 2 stories in 3 months


M. Tezer Kutluk: 2025 Update of World Cancer Declaration with UICC Board / OncoDaily

oncodaily - M. Tezer Kutluk, Professor of Pediatrics and Pediatric Oncologists, Chair of the Scientific Board at Medicana Health Group, shared a post on LinkedIn: “Dear friends, Between 18–20 November 2025 in Melbourne, […]

#healthcare #publichealth


Geriatric Oncology Updates


Global Cancer Leadership & Policy


Innovative Cancer Treatment & Research


Other Cancer & Related Topics


Monday, November 24, 2025, 4:21 am / permalink 16241 / 47 stories in 3 months


New nasal nanodrops wipe out brain tumors in mice / Science Daily Cancer

sciencedaily - A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach the brain without invasive surgery. When paired with dru…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, November 22, 2025, 1:21 pm / permalink 16217 / 3 stories in 3 months


Back to Top


HEALTHCARE Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.